– Iambic Therapeutics, a US-based clinical-stage biotechnology company, has secured an additional $50 million in Series B extension funding, led by Mubadala Capital.
– This extension builds on a $100 million Series B round completed in October 2023, co-led by Ascenta Capital and Abingworth, with participation from NVIDIA and others.
– The funds will be used to advance Iambic’s pipeline of clinical and pre-clinical programs, according to a company statement.
Iambic Therapeutics, a US-based clinical-stage biotechnology company, has secured an additional $50 million in Series B extension funding.
The round was led by the UAE’s Mubadala Capital, a subsidiary of Mubadala Investment Company.
Other participants included Qatar Investment Authority, Exor Ventures, and existing investors such as Abingworth, Illumina Ventures, Nexus Venture Partners, Coatue, and Tao Capital Partners.
This extension builds on a $100 million Series B round completed in October 2023, co-led by Ascenta Capital and Abingworth, with participation from NVIDIA and others.
The funds will be used to advance Iambic’s clinical and pre-clinical program pipeline, according to a company statement.
If you see something out of place or would like to contribute to this story, check out our Ethics and Policy section.
